"PRESCRIPTION PATTERNS OF BRONCHODILATOR AND ANTI-INFLAMMATORY THERAPIES IN COPD MANAGEMENT IN A TERTIARY CARE HOSPITAL IN WESTERN RAJASTHAN"
Main Article Content
Keywords
COPD, bronchodilators, inhaled corticosteroids.
Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality globally. Pharmacologic management primarily includes bronchodilators and anti-inflammatory agents. Despite the availability of well-established guidelines like GOLD and NICE, real-world prescription practices often vary.
Objective: To evaluate the prescription patterns of bronchodilator and anti-inflammatory therapies among COPD patients in a tertiary care hospital in Western Rajasthan and assess their adherence to standard treatment guidelines.
Methods: A prospective, observational, cross-sectional study was conducted over 12 months in the outpatient department of a tertiary care teaching hospital. A total of 260 diagnosed COPD patients were enrolled. Data were collected using a structured proforma and analyzed descriptively to determine drug use trends and guideline adherence.
Results: Most patients were male (88.46%) and aged 60–69 years. Salbutamol (53.85%) was the most prescribed bronchodilator, followed by budesonide (37.69%) and ipratropium (36.92%). Combination therapy was more common (66.15%) than monotherapy. The most frequently prescribed fixed-dose combination was ipratropium + salbutamol (20.77%). Overall, the prescription pattern showed moderate alignment with GOLD and NICE recommendations.
Conclusion: Bronchodilators and inhaled corticosteroid-based combinations form the cornerstone of COPD pharmacotherapy in this setting. While the prescription patterns generally adhered to international guidelines, careful consideration of overuse of certain agents and individualized therapy is recommended to enhance patient outcomes.
References
2. National Institute for Health and Care Excellence. NICE Guidelines [CG101]: Chronic Obstructive Pulmonary Disease : Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care (Partial Update). London: National Institute for Health and Care Excellence; 2010. Available from: http://www.nice.org.uk/guidance/cg101. Accessed July 13, 2016.
3. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
4. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
5. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.
6. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-50.
7. Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin. 2011;27(7):1425-1429.
8. Jochmann A, Neubauer F, Miedinger D, et al. General practitioners adherence to the COPD GOLD guidelines : baseline data of the swiss COPD Cohort Study. Swiss Med Wkly. Epub April 21, 2010.
9. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106 (7): 989-997.
10. Lucas AE, Smeenk FW, Smeele IJ, van Schayck CP. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care.Fam Pract. 2008;25(2):86-91.
11. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11): e442.
12. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. Journal of global health 2015; 5(2): 020415.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Jignesh Kumar
Associate Professor, Dept. of Pharmacology, Govt. Medical College, Pali (Rajasthan)
Dr. Pintu Ahari
Associate Professor, Dept. of General Medicine, Govt. Medical College, Dungarpur (Rajasthan)
Dr. Priyanka Meena
Assistant Professor, Dept. of Paediatrics, Pacific Institute of Medical Science, Umarda-Udaipur (Rajasthan)
Dr. Peeyush Damor
Assistant Professor, Dept. of Community Medicine, Govt. Medical College, Dungarpur (Rajasthan)